Research graph
References from Bibliometric and clinical trial landscape of hepatoblastoma (2000–2024): a multi-database analysis of global research. Local targets link to admitted publications; unresolved targets remain external evidence.
Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults
10.1016/j.jhep.2022.04.035 · 2022 · External reference
State of the art and perspectives in pediatric hepatocellular carcinoma
10.1016/j.bcp.2022.115373 · 2023 · External reference
Global burden of hepatoblastoma from 1990 to 2021 and projection to 2030
10.1002/cam4.71163 · 2025 · External reference
The treatment of hepatoblastoma: its evolution and the current status as per the SIOPEL trials
10.4103/0971-9261.142001 · 2014 · External reference
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
10.1056/nejmoa0810613 · 2009 · External reference
Sodium thiosulfate for protection from cisplatin-induced hearing loss
10.1056/nejmoa1801109 · 2018 · External reference
Metastatic human hepatoblastoma cells exhibit enhanced tumorigenicity, invasiveness and a stem cell-like phenotype
10.1016/j.jpedsurg.2022.01.063 · 2022 · External reference
Mechanisms of anticancer drug resistance in hepatoblastoma
10.3390/cancers11030407 · 2019 · External reference
Molecular mechanisms of mTOR-mediated cisplatin response in tumor cells
10.1016/j.heliyon.2024.e41483 · 2025 · External reference
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
10.1038/s41392-021-00762-6 · 2022 · External reference
Wnt/β-catenin signaling as a useful therapeutic target in hepatoblastoma
10.1042/bsr20192466 · 2019 · External reference
Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib
10.1002/1878-0261.70168 · 2026 · External reference
Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children
10.1056/nejmoa1714448 · 2018 · External reference
NTRK fusion-positive cancers and TRK inhibitor therapy
10.1038/s41571-018-0113-0 · 2018 · External reference
Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review)
10.3892/ijo.2024.5676 · 2024 · External reference
Deregulation of Hippo kinase signalling in human hepatic Malignancies
10.1111/j.1478-3231.2011.02646.x · 2012 · External reference
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
10.1056/nejmoa1915745 · 2020 · External reference
Outcomes of patients with hepatocellular carcinoma treated with durvalumab plus tremelimumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 HIMALAYA trial
10.1111/jgh.70422 · 2026 · External reference
A human organoid model of aggressive hepatoblastoma for disease modeling and drug testing
10.3390/cancers12092668 · 2020 · External reference
Global trends and regional differences of hepatoblastoma: a systematic analysis and predictions to 2035 based on the Global Burden of Disease study 2021
10.1186/s12889-025-24407-3 · 2025 · External reference
Bridging the gap: cancer scientific equity, global child health, and distribution of CAR T-cell therapy clinical trials in childhood cancer
10.3389/fped.2025.1611187 · 2025 · External reference
Barriers and opportunities for cancer clinical trials in low- and middle-income countries
10.1001/jamanetworkopen.2025.7733 · 2025 · External reference
The RACE for Children Act at one year: progress in pediatric development of molecularly targeted oncology drugs
10.1080/14737140.2022.2032664 · 2022 · External reference
FDA approval summary: Entrectinib for the treatment of NTRK gene fusion solid tumors
10.1158/1078-0432.ccr-20-2771 · 2021 · External reference
Larotrectinib effective against TRK-fusion-positive cancers
10.1038/nrclinonc.2018.40 · 2018 · External reference
The RACE Act and pediatric trials of adult cancer drugs
10.1542/peds.2024-066920 · 2024 · External reference
A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC)
10.1200/jco.2023.41.4_suppl.tps624 · 2023 · External reference
Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma
10.1200/jco.2021.39.15_suppl.4088 · 2021 · External reference
A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC)
10.1200/jco.2017.35.15_suppl.3049 · 2017 · External reference
A phase 2 and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma (HCC)
10.1200/jco.2018.36.4_suppl.270 · 2018 · External reference
A pilot trial of personalized neoantigen pulsed autologous dendritic cell vaccine as adjuvant treatment in hepatocellular carcinoma
10.1200/jco.2023.41.16_suppl.e14658 · 2023 · External reference
Utilization of tumor-informed circulating tumor DNA in detecting minimal residual disease and guiding adjuvant therapy in liver cancer
10.1200/jco.2024.42.16_suppl.4125 · 2024 · External reference
Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study
10.1016/s1470-2045(13)70272-9 · 2013 · External reference
Vincristine/irinotecan upfront window treatment of high-risk hepatoblastoma: a report from the Children’s Oncology Group (COG) AHEP0731 study committee
10.1200/jco.2016.34.15_suppl.10516 · 2016 · External reference
Hepatocellular carcinoma in children: Does modified platinum- and doxorubicin-based chemotherapy increase tumor resectability and change outcome? Lessons learned from the SIOPEL 2 and 3 studies
10.1200/jco.2014.60.2250 · 2016 · External reference
Two-year results of clinical efficacy of cisplatin in combination with sodium thiosulfate (STS) vs cisplatin alone in a randomized phase III trial for standard risk hepatoblastoma (SR-HB): SIOPEL 6
10.1200/jco.2016.34.15_suppl.10514 · 2016 · External reference
Correction: LncRNA MYLK-as1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGF R-2 signaling pathway in hepatocellular carcinoma
10.1186/s13046-023-02824-9 · 2023 · External reference
Propofol suppresses hepatocellular carcinoma by inhibiting NET1 through downregulating ERK/VEGF signaling pathway
10.1038/s41598-020-67693-0 · 2020 · External reference
β-Catenin and Yes-Associated Protein 1 cooperate in hepatoblastoma pathogenesis
10.1016/j.ajpath.2019.02.002 · 2019 · External reference
Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development
10.18632/oncotarget.20622 · External reference
Clinical outcomes in fibrolamellar hepatocellular carcinoma treated with immune checkpoint inhibitors
10.3390/cancers14215347er · 2022 · External reference
Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma
10.1158/1535-7163.mct-22-0335 · 2023 · External reference
Abstract 4005: Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma
10.1158/1538-7445.am2022-4005 · 2022 · External reference
Patient‐derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management
10.1002/hep.28621 · 2016 · External reference
Two pediatric liver cancers respond very differently to chemotherapy: Current regimens good for hepatoblastoma, but not hepatocellular carcinoma
10.1097/01.cot.0000294783.17277.40 · 2006 · External reference
